Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies

摘要

The introduction of highly active antiretroviral therapy has profoundly modified the management of HIV-associated haematologic malignancies, making aggressive therapy, including autologous or allogeneic stem cell transplantation, a fascinating tool for treating patients [1]. However, HIV infection has been described as a risk factor for poor mobilization [2]. Plerixafor acts by selective and reversible antagonism of CXCR4 on CD34~+ haematopoietic stem cells. This results in disruption of its interaction with CXCL12 (formally SDF1) on bone marrow (BM) stromal cells, that causes a rapid release of stem and progenitor cells from BM into peripheral blood, facilitating their collection through apheresis methods [3,4].